TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38272383
Drug: Antagonist protocol
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antagonist protocol (per-protocol analysis)
Study: 38272555
Drug: High-cholesterol (600 mg)/low-saturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-cholesterol (600 mg)/low-saturated fat (6%) (egg) diet
Study: 38272555
Drug: Low-cholesterol (300 mg)/high-saturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-cholesterol (300 mg)/high-saturated fat (12%) (egg free) diet
Study: 38272555
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet that is high in both cholesterol (600 mg) and saturated fat (12%)
Study: 38273019
Drug: Dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP) administered as a monthly, 3-days course for three consecutive months
Study: 38273252
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen plus acetaminophen
Study: 38273370
Drug: Consequences Of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consequences Of Screening Lung Cancer (COS-LC) questionnaire administered at prespecified timepoints including at enrolment, dependent on screening results.
Study: 38273379
Drug: Alantel cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alantel cream (natural products at high concentrations)
Study: 38273379
Drug: Moisturizing cream
Normalized name: MOISTURIZING CREAM
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizing cream (control)
Study: 38273393
Drug: Titrated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oxygen delivery targeting a blood oxygen saturation of 88-92% during inhalation therapy
Study: 38273408
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg per day of oral CT1812 for 24 weeks
Study: 38273408
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg per day of oral CT1812 for 24 weeks
Study: 38273408
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg or 300 mg per day of oral CT1812 for 24 weeks
Study: 38273617
Drug: Vagus nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus nerve stimulation (1 min once daily)
Study: 38273617
Drug: Vagus nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus nerve stimulation (1 min four times daily)
Study: 38273624
Drug: JNJ-55920839 (0.3-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-55920839 (0.3-15 mg/kg IV or 1 mg/kg SC)
Study: 38279364
Drug: Otilimab 180
Normalized name: Otilimab
DrugBank: Otilimab (DB06303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilimab 180 mg
Study: 38273637
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg twice daily plus placebo
Study: 38273637
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg twice daily plus methotrexate
Study: 38273639
Drug: Sirolimus 2
Normalized name: sirolimus 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus 2 mg once daily
Study: 38274114
Drug: 10 or
Normalized name: K-10 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 or 100 μg rTSST-1v
Study: 38274114
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg rTSST-1v
Study: 38274236
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (ARNI + SGLT2i)
Study: 38274292
Drug: Intermittent theta
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent theta burst stimulation (iTBS) administered to the left dorsolateral prefrontal cortex (DLPFC) for 14 days every 13 weeks
Study: 38274414
Drug: SPL026 (21.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL026 (21.5 mg) administered as a 2-phase IV infusion over 10 minutes (6 mg/5 min and 15.5 mg/5 min)
Study: 38274492
Drug: TAF 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF 25 mg/day with selgantolimod 3 mg orally once weekly (QW)
Study: 38274492
Drug: Selgantolimod 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selgantolimod 1.5 mg QW
Study: 38274807
Drug: Radical concurrent
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical concurrent chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy, followed by adjuvant immunotherapy for at least one year.
Study: 38276920
Drug: Self-reported fair
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported fair or poor oral health
Study: 38277156
Drug: Omnipod insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omnipod insulin delivery system
Study: 38278170
Drug: Pozelimab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pozelimab (30 mg/kg loading dose, followed by weekly subcutaneous doses based on body weight)
Study: 38278217
Drug: Nighttime pistachio
Normalized name: Pistachio
DrugBank: Pistachio (DB10559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nighttime pistachio snack (57 g/d)
Study: 38278364
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol ester (4 g/d)
Study: 38278856
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (CDT)
Study: 38278960
Drug: Dasatinib for
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib for 2 years after re-treatment
Study: 38279085
Drug: Psilocybin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (30 mg)
Study: 38279085
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (5 mg)
Study: 38279124
Drug: DON 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DON 0.1 mg/kg
Study: 38279124
Drug: DON 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: DON 1.0 mg/kg
Study: 38279363
Drug: Otilimab 180
Normalized name: Otilimab
DrugBank: Otilimab (DB06303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilimab 180 mg subcutaneously once weekly for 5 weeks, then every other week until week 10.
Study: 38279364
Drug: Otilimab 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilimab 22.5 mg
Study: 38279364
Drug: Otilimab 45
Normalized name: Otilimab
DrugBank: Otilimab (DB06303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilimab 45 mg
Study: 38279364
Drug: Otilimab 135
Normalized name: Otilimab
DrugBank: Otilimab (DB06303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilimab 135 mg
Study: 38279367
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of subcutaneous anifrolumab
Study: 38279367
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of subcutaneous anifrolumab
Study: 38279368
Drug: Intravenous belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous belimumab (10 mg/kg)
Study: 38279383
Drug: PF-06826647 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06826647 100 mg
Study: 38279402
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2 intravenously)
Study: 38279411
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg or 10 mg twice daily
Study: 38279575
Drug: Piclidenoson 3
Normalized name: Piclidenoson
DrugBank: Piclidenoson (DB05511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piclidenoson 3 mg BID
Study: 38279575
Drug: Piclidenoson 2
Normalized name: Piclidenoson
DrugBank: Piclidenoson (DB05511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piclidenoson 2 mg BID
Study: 38279662
Drug: MDMA 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 0.75 mg/kg
Study: 38279662
Drug: Methamphetamine (MA)
DrugBank: Metamfetamine (DB01577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methamphetamine (MA) 20 mg
Study: 38279910
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy with Timothy grass (SCIT)
Study: 38280003
Drug: AK104 (Cadonilimab)
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK104 (Cadonilimab) therapy
Study: 38280052
Drug: Nanoemulsion curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanoemulsion curcumin (NEC, 200 mg/day)
Study: 38280118
Drug: High tone
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tone therapy (HiToP 191 PNP ®)
Study: 38280181
Drug: Atezolizumab maintenance
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab maintenance therapy
Study: 38280281
Drug: Short-acting bronchodilator
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting bronchodilator (SAB) - 400 µg of salbutamol and 80 µg of ipratropium
Study: 38280281
Drug: Short-acting bronchodilator
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting bronchodilator (SAB)
Study: 38280392
Drug: Laquinimod 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 1.0 mg
Study: 38280448
Drug: Iruplinalkib 180
Normalized name: Iruplinalkib
DrugBank: Iruplinalkib (DB17494)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iruplinalkib 180 mg once daily (7-day run-in at 60 mg once daily)
Study: 38280653
Drug: Faricimab 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faricimab 6.0 mg every 4 weeks for 24 weeks
Study: 38280653
Drug: Aflibercept 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2.0 mg every 4 weeks for 24 weeks
Study: 38281023
Drug: Behavioural intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioural intervention bundles (including theatre, posters, discussions, etc.) aimed at rationalising Watch antibiotic use and improving hygiene and sanitation practices.
Study: 38281089
Drug: Vitamin-K antagonists
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-K antagonists (VKAs)
Study: 38281295
Drug: Rivoceranib 700
Normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoceranib 700 mg once daily
Study: 38281295
Drug: Rivoceranib 700
Normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoceranib 700 mg once daily in ≥4th-line therapy
Study: 38281309
Drug: Macitentan 10
Normalized name: macitentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macitentan 10 mg as monotherapy or in combination with a phosphodiesterase 5 inhibitor
Study: 38281499
Drug: Vi polysaccharide
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi polysaccharide conjugated to tetanus toxoid vaccine (Vi-TT)
Study: 38281579
Drug: Active transcranial
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transcranial direct current stimulation (tDCS) with computerized lexical-semantic treatment (15 sessions, 2-3 times/week, 45 minutes each, tDCS for first 20 minutes)
Study: 38281579
Drug: Sham transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham transcranial direct current stimulation (tDCS) with computerized lexical-semantic treatment (15 sessions, 2-3 times/week, 45 minutes each, tDCS for first 20 minutes)
Study: 38281914
Drug: PD-1 inhibitor-based
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor-based immunotherapy in MSI-H patients
Study: 38282003
Drug: QL1706 plus
Normalized name: QL1706
DrugBank: QL1706 (DB17562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL1706 plus chemotherapy (with or without bevacizumab)
Study: 38282192
Drug: Peanut oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut oral immunotherapy (PTAH)
Study: 38282258
Drug: reduction counseling
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: reduction counseling + nicotine mini-lozenges + encouragement to quit starting 1 month post-randomization (preparation)
Study: 38282258
Drug: preparation (reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: preparation (reduction counseling)
Study: 38282503
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 0.25% bupivacaine
Study: 38283394
Drug: Perioperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative intravenous tranexamic acid (TXA)
Study: 38284768
Drug: MINS (Myocardial
Approvals — FDA: no, EMA: no, PMDA: no
Description: MINS (Myocardial Injury after Noncardiac Surgery) defined as TnI level >59 ng/L
Study: 38285244
Drug: Pharmacological ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological ascorbate (intravenous delivery reaching plasma concentrations ≈ 20 mM)
Study: 38285244
Drug: Transferrin receptor
Normalized name: Transferrin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transferrin receptor expression
Study: 38285445
Drug: 2-dose nonavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose nonavalent HPV vaccine administered 6 months apart
Study: 38285445
Drug: 3-dose HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose HPV vaccine regimen administered to historical controls
Study: 38285446
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (20 mg, followed by 10 mg every 5 minutes)
Study: 38285446
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine sulfate (2 or 3 mg every 5 minutes)
Study: 38285502
Drug: Remote diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote diabetes self-management education (DSME) program including live video education classes, individualized physical activity prescription and counseling, and continuous glucose and wearable physical activity monitoring.
Study: 38286482
Drug: Reteplase (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reteplase (18 mg + 18 mg)
Study: 38286484
Drug: 0.32 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.32 mg/kg tenecteplase
Study: 38286618
Drug: AtoOxy (80/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AtoOxy (80/5 mg)
Study: 38286683
Drug: Daily cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cyclic enteral nutrition administered over 10 hours
Study: 38286683
Drug: Daily cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cyclic enteral nutrition
Study: 38286685
Drug: Trauma-focused art
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused art therapy (TFAT) intervention for 10 weeks
Study: 38286686
Drug: Cryotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy plus compression therapy for 6 weeks after discharge from hospital
Study: 38286691
Drug: Cooling treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling treatment for fever control within the first 48 hours of septic shock
Study: 38286691
Drug: No cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cooling treatment for fever control within the first 48 hours of septic shock
Study: 38286691
Drug: Cooling treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling treatment for fever control
Study: 38286691
Drug: No cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cooling treatment for fever control
Study: 38286736
Drug: Iliopsoas plane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iliopsoas plane block (10 mL 0.75% ropivacaine with 1:200 000 epinephrine)
Study: 38286736
Drug: Sham block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham block (10 mL normal saline)
Study: 38286884
Drug: Adjuvant Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Therapy (AT)
Study: 38286884
Drug: FOLFIRINOX as
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX as Adjuvant Therapy
Study: 38286884
Drug: Adjuvant Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Therapy (AT) Delay
Study: 38287068
Drug: ChulaCov19 50
Normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChulaCov19 50 µg
Study: 38287179
Drug: Gartisertib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gartisertib (250 mg QD) in cohort A2
Study: 38287253
Drug: Iron deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron deficiency (ID) prevalence defined as serum ferritin < 100 µg/L and/or transferrin saturation coefficient (TSAT) < 20%
Study: 38287253
Drug: CRP ≥
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP ≥ 12 mg/L
Study: 38287253
Drug: Treatment that
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment that may influence ID/anemia
Study: 38287346
Drug: Radionuclide therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radionuclide therapy (RNT) targeted against prostate-specific membrane antigen (PSMA)
Study: 38287349
Drug: Standard micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard micronutrient supplement
Study: 38287611
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg bodyweight intravenously followed by weekly subcutaneous injections of 162 mg) after 500 mg methylprednisolone intravenously for 3 days.
Study: 38287923
Drug: Stepped collaborative
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepped collaborative care intervention including care management, cognitive behavioral therapy elements, and psychopharmacology addressing PTSD symptoms.
Study: 38288117
Drug: 2-cycle induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-cycle induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy (cCRT) and consolidation toripalimab
Study: 38288117
Drug: 2-cycle induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-cycle induction chemotherapy followed by concurrent chemoradiotherapy (cCRT) and consolidation toripalimab
Study: 38288731
Drug: Serum urate
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum urate responders (achieved serum urate < 6 mg/dL)
Study: 38288731
Drug: Serum urate
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum urate non-responders (did not achieve serum urate < 6 mg/dL)
Study: 38288741
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 1 × 10^6 allogeneic bone marrow-derived mesenchymal stromal cells
Study: 38288862
Drug: Doublet regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet regimen (cobimetinib 60 mg daily for days 1-21 + niraparib 200 mg daily for days 1-28)
Study: 38288862
Drug: Triplet regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet regimen (cobimetinib 60 mg daily for days 1-21 + niraparib 200 mg daily for days 1-28 + atezolizumab 840 mg on days 1 and 15)
Study: 38288922
Drug: Adalimumab plus
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab plus methotrexate (adalimumab 40 mg subcutaneously every other week + methotrexate 15 mg weekly)
Study: 38288922
Drug: Escalated methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Escalated methotrexate (up to 25 mg weekly)
Study: 38288937
Drug: secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 150 mg no loading dose (NL)
Study: 38288937
Drug: secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 150 mg NL
Study: 38289301
Drug: Oscillatory PEP-therapy
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oscillatory PEP-therapy using Acapella DHGreen device, 10-12 hours after tracheal extubation, 3 times a day for 3 days after surgery.
Study: 38289301
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no respiratory therapy).
Study: 38289301
Drug: Oscillatory PEP-therapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillatory PEP-therapy.
Study: 38289666
Drug: VR therapy
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR therapy (360° VR films on a head-mounted display for up to 20 minutes every 1 to 3 days)
Study: 38290108
Drug: Venetoclax 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 400 mg daily after initial ramp-up until progressive disease
Study: 38290135
Drug: Add-on parsaclisib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on parsaclisib 10 or 20 mg, once daily for 8 weeks, then once weekly thereafter (daily-to-weekly dosing)
Study: 38290135
Drug: Add-on parsaclisib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on parsaclisib 5 or 20 mg, once daily for 8 weeks, then 5 mg once daily thereafter (all-daily dosing)
Study: 38290135
Drug: Add-on parsaclisib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on parsaclisib (daily-to-weekly dosing)
Study: 38290135
Drug: Add-on parsaclisib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on parsaclisib (all-daily dosing)
Study: 38290699
Drug: Cinnamon (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon (4 g/d)
Study: 38290741
Drug: Cold application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold application (cold gel packs applied 12 times for 15 min at 2-h intervals)